SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on April 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.
Read more at globenewswire.comBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Provided By GlobeNewswire – Last update: